STAAR Surgical Company reported its first quarter 2025 financial results, highlighting a significant decrease in net sales and increased net loss. Net sales totaled $42.6 million, marking a 45% decline year-over-year, primarily due to a planned reduction of channel inventory in China. Excluding China, net sales were $42.2 million, reflecting a 9% increase from the previous year, driven by growth in all key markets. The company posted a net loss of $54.2 million, compared to a net loss of $3.3 million for the same period in the previous year. This decline in net income was largely due to lower net sales and restructuring charges. Gross margin decreased to 65.8% from 78.9% the previous year, attributed to an intentional reduction in U.S. production volumes and preparations for manufacturing in Switzerland. STAAR Surgical is experiencing improved EVO ICL procedure trends in China, despite macroeconomic challenges, and has implemented tariff mitigation activities and cost control measures to reduce its SG&A run rate. Cash, cash equivalents, and investments available for sale stood at $222.8 million as of March 28, 2025.